Protalix BioTherapeutics (PLX) EBT (2010 - 2026)

Protalix BioTherapeutics' EBT history runs 17 years deep, the most recent figure standing at $21.1 million for Q1 2026.

• In Q1 2026, EBT rose 666.48% year-over-year to $21.1 million; the TTM figure through Mar 2026 stood at $20.3 million (up 109.15% YoY), while the FY2025 annual figure was -$4.6 million, down 152.62% from the prior year.
• EBT was $21.1 million for Q1 2026 at Protalix BioTherapeutics, up from -$3.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $21.1 million in Q1 2026 to a low of -$22.1 million in Q4 2023.
• Historically, EBT has averaged $223882.4 across 5 years, with a median of -$2.3 million in 2022.
• The sharpest annual moves came in 2023 and 2026: EBT tumbled 587.01% in 2023, then surged 666.48% in 2026.
• A 5-year view of EBT shows it stood at -$3.2 million in 2022, then sank by 587.01% to -$22.1 million in 2023, then surged by 153.8% to $11.9 million in 2024, then sank by 131.58% to -$3.7 million in 2025, then jumped by 664.21% to $21.1 million in 2026.
• The last three EBT figures came in at $21.1 million (Q1 2026), -$3.7 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.